ArticleJAC-antimicrobial resistance2025
Comparative effectiveness of adjunctive rifampicin versus gentamicin for prosthetic valve endocarditis due to
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment of Methicillin-ResistantMedicines (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although adjunctive rifampicin and/or gentamicin have been recommended for Objectives: To compare the clinical impact of adjunctive rifampicin without gentamicin, and adjunctive gentamicin without rifampicin therapies for Methods: This retrospective study used TriNetX to evaluate multicentre electronic medical records of patients aged 18 years or older in the USA between 2016 and 2024. After propensity score matching, HRs were estimated with 95% CIs. Covariates included age, sex, ethnicity and medical comorbidities. Results: A total of 353 and 369 patients were identified in the rifampicin and gentamicin groups, respectively. One-year all-cause mortality was observed in 87 (31.3%) and 111 (39.9%) patients in the rifampicin and gentamicin groups after propensity score matching, respectively, leading to an HR of 0.71 (95% CI, 0.54-0.94; Conclusions: The rifampicin-containing regimen without gentamicin was associated with reduced 1 year mortality compared with the gentamicin-containing regimen without rifampicin. Although the results should be interpreted with caution because of potential residual unmeasured confounders, including duration of antimicrobial treatment and biases, our findings provide further evidence that adjunctive gentamicin may not be routinely needed for
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.